The collaboration validates Telix’s platform and de-risks its pipeline through a partnership with a top-tier biotech. Traders should monitor program progression and any opt-in/opt-out decisions on co-funding, which will impact future revenue streams and capital allocation.
TLX drugs
TLX drug pipeline →- ◆ ITM-11 4/10 Phase 3 (completed)
- ● TLX591-Tx 4/10 Phase 3
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $11.24entry
- T+1 · 7mo ago −4.80%α −6.01% · $10.70
- T+5 · 7mo ago −4.54%α −7.83% · $10.73
- T+20 · 6mo ago −3.65%α −11.38% · $10.83
- T+60 · 4mo ago +2.76%α −6.16% · $11.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Telix Pharmaceuticals announced a strategic collaboration with Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Telix will receive an upfront payment of $40 million and has the option to earn up to $2.1 billion in aggregate milestone payments plus royalties if it opts out of co-funding. The partnership combines Telix’s radiopharmaceutical expertise with Regeneron’s antibody discovery platforms.
Key Financial Metrics
Key Facts
- Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceuticals in a 50/50 cost and profit-sharing model.
- Telix to receive $40 million upfront from Regeneron for four initial programs.
- If Telix opts out of co-funding for a program, it can earn up to $535 million in milestones per program, with a total potential of $2.1 billion across multiple programs, plus low double-digit royalties.
- Collaboration includes multiple solid tumor targets using Regeneron’s VelocImmune®-derived antibodies and joint development of radio-diagnostic tools.
- Telix retains option to co-promote certain products and will lead commercialization of diagnostic assets.
Financial Impact
$40 million upfront payment received; potential for up to $2.1 billion in milestone payments and low double-digit royalties; 50% share of profits if co-funding is pursued.
Risk Factors
- Execution risk in joint development and regulatory timelines.
- Potential disputes or misalignment with Regeneron on program priorities.
- Uncertainty in achieving clinical and commercial milestones necessary to trigger payments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272316 |
Track record
27 reports on TLX
10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers